The glycoconjugate (neoglycopeptide)-based vaccine candidate is structurally simple, chemically-stable, and efficiently produced in a large-scale. The effect of the alpha-Gal-containing glycotope position within the vaccine molecule on the immune responses is explored for the first time. The synthetic Galα3LN and closely-related neoglycopeptides are used as candidates for this preventative and therapeutic vaccine. Chao Zhang czhang3@utep.edu 915-747-6717
Smart, interactive desk
May 8, 2023
No Comments
Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the